Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0010511,
umls-concept:C0016006,
umls-concept:C0016016,
umls-concept:C0032143,
umls-concept:C0150312,
umls-concept:C0205265,
umls-concept:C0205390,
umls-concept:C0439834,
umls-concept:C0443286,
umls-concept:C0936012,
umls-concept:C1522492,
umls-concept:C1555582,
umls-concept:C1622667,
umls-concept:C1708096,
umls-concept:C1948023
|
pubmed:issue |
15
|
pubmed:dateCreated |
1988-6-20
|
pubmed:abstractText |
Plasminogen activation by tissue-type plasminogen activator (t-PA) is stimulated by fibrin. In a purified system maximal fibrin-enhanced plasmin formation occurs with a delay after an initial phase of slow plasmin formation (lag phase). In the present study purified stimulating CNBr-fragment FCB-2 of fibrinogen was used, and kinetics of plasminogen activation by t-PA were analyzed with respect to the lag phase. At constant FCB-2 concentration the duration of the lag phase decreased with increasing concentrations of t-PA and plasminogen. During this period the rate of plasmin formation/min increased linearly with time with a slope dependent on the initial concentrations of FCB-2, plasminogen, and t-PA. Plasmin pretreatment of FCB-2 resulted in a dose- and time-dependent shortening of the lag phase, and at plasmin concentrations greater than or equal to 1 nM and preincubation times greater than or equal to 3 min maximal plasmin formation occurred without a lag phase. Kinetics during the phase of maximal and constant plasmin formation were not influenced by plasmin pretreatment of FCB-2. We therefore conclude that maximal t-PA-dependent plasmin formation in a system stimulated by purified FCB-2 requires plasmin modification of FCB-2.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyanogen Bromide,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolysin,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0021-9258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
25
|
pubmed:volume |
263
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
7176-80
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:2966802-Cyanogen Bromide,
pubmed-meshheading:2966802-Enzyme Activation,
pubmed-meshheading:2966802-Fibrinogen,
pubmed-meshheading:2966802-Fibrinolysin,
pubmed-meshheading:2966802-Humans,
pubmed-meshheading:2966802-Kinetics,
pubmed-meshheading:2966802-Peptide Fragments,
pubmed-meshheading:2966802-Plasminogen,
pubmed-meshheading:2966802-Tissue Plasminogen Activator
|
pubmed:year |
1988
|
pubmed:articleTitle |
Plasminogen activation by tissue plasminogen activator in the presence of stimulating CNBr fragment FCB-2 of fibrinogen is a two-phase reaction. Kinetic analysis of the initial phase of slow plasmin formation.
|
pubmed:affiliation |
Department of Medical Physiology, University of Vienna, Austria.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|